1-6 of 6
Rushdia Yusuf
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Pembrolizumab in Children, Adolescents, and Young Adults with Low-Risk Classic Hodgkin Lymphoma (cHL) and Slow Early Response to Front-Line Chemotherapy: Updated Results from the Phase 2 Keynote-667 Study

Lisa Giulino Roth, Mario Melgar Toledo, Frank G. Keller, Bradford Hoppe, Christopher J. Forlenza, Sharon M. Castellino, Maitane Andión Catalan, Julie Krystal, Adam Lamble, Flavio Luisi, Fabio Molina Morales, Aarati V. Rao, Stacy Cooper, Oscar Gonzalez Llano, Luis Juarez Villegas, Christine Mauz-Koerholz, Juan Shen, Pallavi Pillai, Rushdia Yusuf, Kara M. Kelly
Journal: Blood
Blood (2024) 144 (Supplement 1): 462.
https://doi.org/10.1182/blood-2024-199263
Published: 2024
Journal Articles

Waveline-007: Dose Escalation and Confirmation, and Efficacy Expansion Trial of Zilovertamab Vedotin in Combination with Cyclophosphamide, Doxorubicin, and Prednisone Plus Rituximab in Patients with Diffuse Large B Cell Lymphoma

Muhit Ozcan, Eva Gonzalez Barca, Tae Min Kim, Ewa Paszkiewicz-Kozik, Jan M. Zaucha, Stefan Hohaus, Marco Ladetto, Caterina Patti, Sebastian Giebel, Tadeusz Robak, Ömür Gökmen Sevindik, Yulia Volchek, Benedetta Puccini, Guillermo Rodríguez Garcia, Raul Cordoba, Okan Seyran, Siruo Wang, L. Puja Patel, Rushdia Yusuf, David Lavie
Journal: Blood
Blood (2024) 144 (Supplement 1): 578.
https://doi.org/10.1182/blood-2024-200271
Published: 2024
Journal Articles

Pembrolizumab in Children, Adolescents, and Young Adults with High-Risk Classic Hodgkin Lymphoma (cHL) with Slow Early Response to Front-Line Chemotherapy: Updated Results from the Phase 2 Keynote-667 Study

Christine Mauz-Koerholz, Luciana Vinti, Stephen Daw, Antony Ceraulo, Gerard Michel, Michaela Cepelova, Lorena Valero-Arrese, Franca Fagioli, Stéphane Ducassou, Salvatore Buffardi, Thierry Leblanc, Bradford S Hoppe, Frank G. Keller, Kara M. Kelly, Lisa Giulino Roth, Judith Landman-Parker, Juan Shen, Pallavi Pillai, Rushdia Yusuf, Auke Beishuizen
Journal: Blood
Blood (2024) 144 (Supplement 1): 3055.
https://doi.org/10.1182/blood-2024-199675
Published: 2024
Journal Articles

Efficacy and Safety of Pembrolizumab Every Six Weeks in Relapsed/Refractory Classical Hodgkin Lymphoma or Primary Mediastinal B-Cell Lymphoma: Keynote-B68 Update

Andrew Bruce McDonald, Estelle Verburgh, Manuel Gotti, Antonio Pinto, Jan M. Zaucha, Vladimir Ivanov, Vladimir Melnichenko, Heidi Mocikova, Muhit Ozcan, Caterina Patti, João Farias, Iara Zapparoli Goncalves, Olha Kuchkova, Jiri Mayer, Güray Saydam, Sarah Tomassetti, Kumudu Pathiraja, Katherine Ryland, Rushdia Yusuf, Wojciech Jurczak
Journal: Blood
Blood (2024) 144 (Supplement 1): 3046.
https://doi.org/10.1182/blood-2024-200323
Published: 2024
Journal Articles

Updated Results from the Phase 2 Waveline-004 Study of Zilovertamab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Lalita Norasetthada, Joaquin Diaz, Fangfang Lv, Yuqin Song, Seung Tae Lee, Ewa Paszkiewicz-Kozik, Dipenkumar Modi, Armando Santoro, Kumudu Pathiraja, Nishitha Reddy, Rushdia Yusuf, Muhit Ozcan
Journal: Blood
Blood (2024) 144 (Supplement 1): 1738.
https://doi.org/10.1182/blood-2024-201522
Published: 2024
Journal Articles

Safety and Efficacy of Vibostolimab and Pembrolizumab in Patients with Relapsed or Refractory Hematologic Malignancies: A Multicohort, Open-Label, Phase 2 Study

Rushdia Yusuf, Thomas Jemielita, Patricia Marinello
Journal: Blood
Blood (2021) 138 (Supplement 1): 2484.
https://doi.org/10.1182/blood-2021-151728
Published: 2021